Welcome to our dedicated page for Pro-Dex Colo SEC filings (Ticker: PDEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pro-Dex, Inc. (NASDAQ: PDEX) SEC filings page provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Pro-Dex operates in the surgical and medical instrument manufacturing industry, focusing on autoclavable, battery-powered, and electric multi-function surgical drivers and shavers for orthopedic, thoracic, and maxocranial facial markets, and its filings give detailed insight into how this business is structured and managed.
Through this page, readers can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which include discussions of net sales, gross profit, operating expenses, operating income, and the effects of product mix, repair programs, and costs such as tariffs. These filings also describe the importance of Pro-Dex’s largest customer, shipments of next generation orthopedic handpieces, and repair revenue for legacy products, all of which are central to understanding the company’s revenue profile.
Users can also examine current reports on Form 8-K, where Pro-Dex discloses material events such as earnings announcements, contract developments, executive and director compensation decisions, equity incentive awards, and the results of its annual meeting of shareholders. For example, recent 8-K filings detail restricted share grants under the company’s equity incentive plan, discretionary cash bonuses for executives, and shareholder voting outcomes on director elections, auditor ratification, and amendments to the equity incentive plan.
In addition, the proxy statement filed on Form DEF 14A provides information on corporate governance, board composition, executive compensation, and proposals submitted to shareholders. Together, these documents offer a comprehensive view of Pro-Dex’s financial reporting, governance practices, and key risks and opportunities.
On Stock Titan, Pro-Dex filings are updated from EDGAR and accompanied by AI-powered summaries that highlight the main points of lengthy 10-Ks, 10-Qs, and 8-Ks, helping readers quickly understand what has changed. The platform also makes it easier to navigate to filings related to executive and director compensation, equity plans, and other matters that can influence shareholders’ evaluation of PDEX.
Pro-Dex, Inc. (PDEX) director Katrina Marie Kramer Philp reported an equity grant from the company. On 11/20/2025 she received 1,000 shares of common stock as an award of restricted shares under Pro-Dex’s 2016 Equity Incentive Plan at a stated price of $0.00 per share. After this grant, she beneficially owns 2,000 common shares directly and 14,696 common shares indirectly through her spouse.
The restricted shares vest in equal installments over five years following the grant date, and vesting depends on her continued service to Pro-Dex during that period. The filing is made as a Form 4 for a single reporting person in her capacity as a director of the company.
Pro-Dex, Inc. (PDEX) director David C. Hovda reported receiving a grant of 1,000 shares of Pro-Dex common stock on 11/20/2025. The filing shows these shares were acquired at a stated price of $0, reflecting a restricted stock award rather than an open‑market purchase. Following this grant, Hovda beneficially owns 4,300 Pro-Dex shares in direct ownership.
The 1,000 restricted shares were granted under Pro-Dex’s 2016 Equity Incentive Plan. They vest in equal installments over five years after the grant date, as long as Hovda continues to provide service to Pro-Dex during the vesting period. This Form 4 simply records the equity compensation awarded to a board member and the resulting change in his share ownership.
Pro-Dex, Inc. (PDEX) director received a grant of 1,000 shares of common stock on 11/20/2025. The shares were granted at a price of $0.00 under the company’s 2016 Equity Incentive Plan as restricted stock.
These restricted shares vest in equal installments over the five years following the grant date, and vesting depends on the director’s continued service to Pro-Dex during this period. After this grant, the reporting person beneficially owns 2,000 shares directly and 5,100 shares indirectly through an IRA.
Pro-Dex, Inc. (PDEX) director equity activity shows a small tax-related share forfeiture and a new restricted stock grant. On 11/20/2025, the reporting director forfeited 72 shares of common stock at a price of $30.83 to cover payroll taxes tied to the vesting of 200 restricted shares that were granted on 11/20/2024 under Pro-Dex's 2016 Equity Incentive Plan. On the same date, the director received a grant of 1,000 restricted common shares for no cash payment, also under the 2016 Equity Incentive Plan. These restricted shares vest in equal installments over five years, contingent on continued service with Pro-Dex. After these transactions, the director beneficially owned 15,447 common shares, held directly.
Pro-Dex, Inc. (PDEX) filed a Form 4 showing equity-related transactions by its Chief Financial Officer, Alisha Charlton. On 11/20/2025, 72 shares of common stock were forfeited at a price of $30.83 per share to cover payroll taxes tied to the vesting of 200 restricted shares granted on 11/20/2024 under the company’s 2016 Equity Incentive Plan. On the same date, Charlton received a grant of 1,000 restricted shares at a price of $0, also under the 2016 Equity Incentive Plan. Following these transactions, she beneficially owned 17,267 shares of Pro-Dex common stock directly. The newly granted restricted shares vest in equal installments over five years, as long as she continues her service with Pro-Dex over the vesting period.
Pro-Dex, Inc. (PDEX) reported an insider equity award for director and 10% owner Raymond E. Cabillot. On 11/20/2025 he acquired 1,000 shares of common stock at a price of $0.00, described as a grant of restricted shares under the company’s 2016 Equity Incentive Plan.
Following this grant, he beneficially owns 2,000 common shares directly and 270,846 common shares indirectly through Farnam Street Partners, L.P. This filing is a standard Form 4 disclosure of insider ownership and compensation in stock.
Pro-Dex, Inc. reported compensation actions and shareholder voting results. The Compensation Committee granted restricted common shares under its 2016 Equity Incentive Plan to non-employee directors and select employees, including 1,000 restricted shares to CFO Alisha K. Charlton, vesting in equal installments over five years, generally contingent on continued employment.
The Committee also approved a discretionary cash bonus to CEO Richard L. Van Kirk of $30,830, equal to the value of 1,000 shares based on the Nasdaq Capital Market closing price on November 20, 2025, to be paid in the next bi-weekly pay period. At the 2025 Annual Meeting, all director nominees were elected, shareholders ratified the company’s independent registered public accounting firm, approved on an advisory basis the compensation of Named Executive Officers and chose an annual advisory vote on that pay, and approved an additional proposal.
Pro-Dex, Inc. furnished a Form 8-K announcing it is issuing a press release covering financial performance for its first fiscal quarter ended September 30, 2025. The Item 2.02 information is expressly furnished, not filed for purposes of Section 18 of the Exchange Act. The press release is included as Exhibit 99.1.
Pro-Dex, Inc. reported stronger quarterly results. Net sales were $18.53 million, up 24% year over year, as orthopedic product shipments recovered and CMF drivers grew. Gross margin was 29% versus 35% a year ago, reflecting higher product costs, under‑absorption, and lower repair margins.
Operating income was $3.11 million. Other income rose to $3.11 million, including $3.30 million of unrealized gains on investments. Net income was $4.68 million, with diluted EPS of $1.40. Cash was $0.51 million and investments measured at fair value totaled $10.19 million. Working capital was $37.12 million. Notes payable were $13.28 million, and $2.16 million was drawn on the revolving loan.
Backlog was approximately $46.8 million, with $43.6 million scheduled for delivery during the remainder of fiscal 2026. Customer concentration remained high: one customer represented 78% of revenue and 84% of gross receivables. After quarter‑end, Pro-Dex received $8.9 million in cash from the Monogram sale and expects to record a $6.8 million realized gain in the next quarter; it also received contingent value rights tied to future milestones.
Pro‑Dex, Inc. discloses ownership, governance, compensation and equity-plan details in its definitive proxy. There are 3,280,004 shares outstanding and a group of directors, named executives and related parties hold 1,505,896 shares (45.9%). AO Partners I, L.P. holds 922,204 shares and those shares are pledged as collateral for a bank loan.
Board biographies highlight long tenure and industry experience in finance and medical devices. Executive pay descriptions show base salaries (CEO base noted at $350,000 and another executive at $247,200), year-by-year total compensation figures, and a pay-for-performance approach where bonuses tie to revenues, profit, cash flow and stock price. Outstanding equity awards include 237,250 non-qualified stock options (79,750 vested) and restricted/performance shares; the shareholder‑approved plan caps issuance at 1,500,000 shares.